ArticlePregnancy (Hoboken, N.J.)2025
Maternal laparotomy to fetoscopic myelomeningocele repair in patients with Class 2 obesity is safe and feasible.
Article in Pregnancy (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is minimal to no data on fetal surgery outcomes in the setting of body mass index (BMI) ≥ 35. Theoretical concerns exist for increased maternal risks from surgery and increased surgical difficulty due to maternal body habitus. Objective: To evaluate the pregnancy and operative outcomes with maternal laparotomy to 3-port fetoscopic myelomeningocele (MMC) repair in the setting of pre-pregnancy BMI 35-40 compared with pre-pregnancy BMI < 35. Methods: This was a cohort study at a single maternal fetal care center in which maternal laparotomy to 3-port fetoscopic surgery for MMC was performed. Criteria for offering surgery were same as the Management of Myelomeningocele Study (MOMS) Trial with the exception that, starting in 2022, our center's BMI criterion was increased to include pre-pregnancy BMI ≤ 40. The primary outcome was the gestational age of delivery after surgery. Secondary outcomes planned were operative times, birthweight, and postoperative maternal and fetal complications. Evaluation of non-inferiority was planned on the primary outcome and operative times, with a < 1 week decrease in gestational age at delivery in the setting of repair with BMI ≥ 35 being considered non-inferior. Results: From January 2022 to December 2024, there were a total of 38 pregnancies that both underwent maternal laparotomy to fetoscopic MMC repair and delivered prior to December 2024. A total of 12 patients had a pre-pregnancy BMI 35-40. Patients were similar regarding pregnancy characteristics. Regarding the primary outcome, there was no difference in gestational age at delivery between groups (36 2/7 weeks, IQR 34 3/7, 37 5/7 in BMI 35-40 vs. 35 2/7 weeks, IQR 31 4/7, 37 4/7 in BMI < 35, Conclusion: Maternal laparotomy to fetoscopic MMC repair patients with BMI 35-40 is non-inferior to that of patients with BMI < 35. With the exception of a slightly longer non-fetoscopic surgery time, the characteristics and pregnancy outcomes are similar between groups. BMI 35-40 should not by itself be considered an absolute contraindication to in utero MMC repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.